2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Hematopoiesis, Immune Mechanism, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, LGL, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4920 Predictors of myeloid neoplasm transformation and overall survival in a unified dataset of bone marrow failure syndromes

Markie Zimmer, MD, Yan Li, PhD2, Alexia Kessler3, Xi Zhang, MD, PhD4, Kimberly Langer, CNP5, Saubia Fathima, MD6, Laura Ongie, MS, CGC7, Terra Lasho, PhD8, Alejandro Ferrer, PhD9, Anand Srinivasan, MBBS10, Mira A. Kohorst, MD11, Ahmad Al-Huniti, MD12, Surbhi Shah, MBBS, MD13, Talha Badar, MD14, Ajoy Lawrence Dias, MD15, Tariq Kewan, MD16, William Hogan, M.B., B.Ch.17, Naseema Gangat, MBBS18, Aref Al-Kali, M.D.19, Hassan B Alkhateeb, M.D.20, Mithun Shah, MD, PhD21, Mehrdad Hefazi Torghabeh, MD22, Aasiya Matin, MBBS23, Yael Kusne, MD, PhD24, James Foran, FRCPC25, Mrinal M. Patnaik, MD, MBBS26, Abhishek Avinash Mangaonkar, MBBS27
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Phoenix, Arizona, United States
9 Mayo Clinic, Phoenix, Arizona, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Phoenix, Arizona, United States
14 Mayo Clinic, Jacksonville, Florida, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Phoenix, Arizona, United States
25 Mayo Clinic, Jacksonville, Florida, United States
26 Mayo Clinic, Rochester, Minnesota, United States
27 Mayo Clinic, Rochester, Minnesota, United States

Introduction: Bone marrow failure syndromes (BMFS) comprise a heterogenous group of diseases with unique but overlapping clinical features. At present, etiopathogenesis-based diagnosis guides therapeutic decision-making. Genomic and functional tests are instrumental in distinguishing these diagnoses; however, they may not always be available in a timely manner or have sufficient discriminant capacity. While several prediction models and algorithms differentiate between the diagnostic subtypes, there are no established prognostic models to predict myeloid neoplasm (MN) transformation or survival.

Methods: After IRB approval, we compiled a database of patients with BMFS diagnosed between 1991 and 2026. Inclusion criteria required at least one persistent (>=3 month) cytopenia with bone marrow hypocellularity; absence of malignancy at diagnosis; absence of nutritional deficiencies or therapy exposure; absence of germline hematologic malignancy predisposition states, such as DDX41, RUNX1, ANKRD26. Detailed clinical, genomic and treatment data were obtained. All diagnoses were independently and centrally reviewed by a hematologist and a hematopathologist. Diagnostic subtype was assigned only if both experts concurred (concordance rate 95%; non-concordant diagnoses were classified as undefined). Cox proportional hazard model was built, and its discriminant capacity was assessed using Harrell’s C index. Hematologic responses were documented as per RACE trial criteria (De latour RP et al. NEJM 2022). Statistical analysis was performed using JMP (v17), GraphPad Prism (v11) and MedCalc (v23.6.4).  

Results: Overall, 162 patients met study criteria with a median age of 32 (0-71) years at diagnosis, with 95 (59%) females. Clinical parameters at diagnosis or first referral included a hemoglobin 9.8 (3.5-17.3) g/dL, MCV 99.8 (73-130) fL, platelet 45 (1-377) x10^3/uL, ANC 1.3 (0-8.7) x10^3/uL, ALC 1.3 (0-5.4) x10^3/uL and absolute reticulocyte count (ARC) 55 (0-254) x10^9/L. Bone marrow cellularity was 20% (0-70). Twenty-eight patients (17%) had severe (n=16) or very severe (n=12) disease by Camitta criteria.

Seventy-one (44%) had aplastic anemia, 63 (39%) had IBMFS and 28 (17%) had undefined BMFS. Telomere biology disorders (TBD) represented the majority of the IBMFS cohort with 39 patients (62%), followed by FA in 9 patients (15%). Thirty-nine patients had pathogenic germline mutations at diagnosis, most commonly TERT in 7 patients (18%), GATA2 in 6 (15%), FANC group genes in 4 (10%), ERCC6L2 in 3 (8%), TINF2 in 2 (5%), bi-allelic CECR1 in 2 (5%), DKC1 in 2 (5%) and bi-allelic SBDS in 2 (5%). Among the 28 patients with somatic mutations at diagnosis or first referral, ASXL1 was most common in 7 (25%), followed by U2AF1 in 4 (14%), BCOR in 4 (13%), and TP53 in 3 (11%).

In terms of therapy, 68 (42%) underwent allogeneic HCT and were censored at the time of transplant. Of the ninety-eight patients who received non-transplant treatment, 41 (42%) received at least one form of IST (anti-thymocyte globulin (ATG)-42, cyclosporine-51, mycophenolate mofetil-1, tacrolimus-1 or alemtuzumab-1). Ten of 18 (56%) evaluable patients responded [CR (n=9) 50%, PR (n=1) 6%] to IST.  

Eighteen patients (11%) developed MN (MDS-13, AML-3, CMML-1, unspecified leukemia-1). Presence of any somatic mutation (P<0.0001) and ASXL1 mutation (P<0.0001) predicted MN development (P<0.0001).  

At median follow-up of 6 years, 131 (81%) were alive. In a univariable model, older age (age>50 years) (HR=6, P<0.0001), IBFMS (HR=2.5, P=0.03-specifically TBD), absolute monocytosis (monocyte count>=0.5, HR=7, P=0.0003) & extra-hematopoietic features (HR=3, P=0.004; specifically, ILD) were predictive of adverse transplant-censored overall survival (TCOS), but not somatic or ASXL1 mutation or response to IST. In a multivariable model that included the aforementioned variables, only older age remained significant (HR=7, P=0.0006). The 1- and 2-year cumulative incidence of myeloid neoplasm, competing with death, was higher in TBD than in AA (10% vs. 2% and 15% vs. 5%, respectively; P=0.008). For predicting TCOS, we fit a Cox model using baseline age, extra-hematopoietic features, and ASXL1 mutation with a C-index of 0.749.

Conclusions: A pragmatic disease-agnostic model integrating readily available clinical and genomic features was able to discriminate pre-transplant mortality across BMFS. ASXL1 mutations remained strongly associated with myeloid-neoplasm development.

Markie Zimmer, MD: Bristol Myers Squibb - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)